Letter: tenofovir may be superior to entecavir for treatment-naive chronic hepatitis B patients

被引：2
|
作者：
Wang, Ji-Gan [1 ]
Chen, Rui [1 ]
Wang, Li-Chuan [1 ]
机构：
[1] Maternal & Child Hlth Hosp Guangxi Zhuang Autonom, Nanning, Peoples R China
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2021年 / 53卷 / 09期
关键词：
HEPATOCELLULAR-CARCINOMA; VIRAL LOAD; MORTALITY; RISK; HBV;
D O I：
10.1111/apt.16323
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1048 / 1049
页数：2
相关论文
共 50 条
  • [21] Reply to: "Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea''
    Kim, Beom Kyung
    JOURNAL OF HEPATOLOGY, 2020, 72 (01) : 198 - 199
  • [22] Clinical efficacy of tenofovir and entecavir in the treatment of chronic hepatitis B infection in patients naive to nucleosides and their analogues therapy
    Zhang, Defa
    Li, Shuang
    Lu, Wei
    Ma, Ping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (08): : 12329 - 12335
  • [23] Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t) ide-naive patients with chronic hepatitis B
    Kwon, Y. J.
    Lee, H. S.
    Park, M. J.
    Shim, S. G.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2015, 18 (06) : 796 - 801
  • [24] Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir
    Ridruejo, Ezequiel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (23) : 7169 - 7180
  • [25] Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
    Lee, Sung Won
    Kwon, Jung Hyun
    Lee, Hae Lim
    Yoo, Sun Hong
    Nam, Hee Chul
    Sung, Pil Soo
    Nam, Soon Woo
    Bae, Si Hyun
    Choi, Jong Young
    Yoon, Seung Kew
    Han, Nam Ik
    Jang, Jeong Won
    GUT, 2020, 69 (07) : 1301 - 1308
  • [26] Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B
    Chon, Hye Yeon
    Lee, Jae Seung
    Lee, Hye Won
    Chun, Ho Soo
    Kim, Beom Kyung
    Tak, Won Young
    Park, Jun Yong
    Kweon, Young-Oh
    Kim, Do Young
    Ahn, Sang Hoon
    Jang, Se Young
    Park, Soo Young
    Kim, Seung Up
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (04) : E794 - E807
  • [27] Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naive patients with chronic hepatitis B following entecavir therapy
    Jeong, Joonho
    Shin, Jung Woo
    Jung, Seok Won
    Lee, Seung Bum
    Park, Eun Ji
    Park, Neung Hwa
    HEPATOLOGY RESEARCH, 2021, 51 (09) : 923 - 932
  • [28] Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir
    Fong, Tse-Ling
    Tien, Andy
    Jo, Kahee J.
    Chu, Danny
    Cheung, Eddie
    Mena, Edward A.
    Quang-Quoc Phan
    Yu, Andy S.
    Mohammed, Wafa
    Velasco, Andrew
    Vinh-Huy LeDuc
    Nguyen, Nickolas
    Han, Steven-Bui
    Chang, Mimi
    Bae, Ho S.
    Cho, Yong-Won
    Tong, Myron J.
    Cooper, Stewart L.
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (11) : 3465 - 3472
  • [29] Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis
    Shim, Ju Hyun
    Lee, Han Chu
    Kim, Kang Mo
    Lim, Young-Suk
    Chung, Young-Hwa
    Lee, Yung Sang
    Suh, Dong Jin
    JOURNAL OF HEPATOLOGY, 2010, 52 (02) : 176 - 182
  • [30] ENTECAVIR RESISTANCE IN ENTECAVIR NAIVE LAMIVUDINE TREATED CHRONIC HEPATITIS B PATIENTS
    Sayan, Murat
    Hulagu, Sadettin
    Akhan, Sila Cetin
    Senturk, Omer
    Meric, Meliha
    Cekmen, Mustafa
    MIKROBIYOLOJI BULTENI, 2009, 43 (03): : 425 - 432
12345